• Phone
  • Contact us
  • Locations
  • Search
  • Menu

share

  • Add this article to your LinkedIn page
  • Add this article to your Twitter feed
  • Email this article
View or print a PDF of this page
.

"We need to make sure that all the institutions taking part follow common procedures, from obtaining consent to the lab testing itself."

 

IAN RHODES, EXPERT IN TECHNOLOGY AND HEALTHCARE,  PA CONSULTING GROUP

Gene test promises cancer care gains

Financial Times
Clive Cookson
22 August 2011

 

PA’s Ian Rhodes, head of technology and healthcare, is quoted in the Financial Times. The article looks at moves to develop a new generation of personalised cancer treatments when the world’s first nationwide genetic testing programme for cancer patients starts in the UK next month.  

Cancer Research UK is leading the new Stratified Medicine Programme, which is designed to tailor each patient’s treatment to the genetic nature of the tumour. Stratified medicine represents a move towards personalised medicine, in which everyone’s treatment is based on his or her individual genetic characteristics. PA is providing managerial and information technology services to the programme.

Commenting on the testing programme, Ian Rhodes says: “We need to make sure that all the institutions taking part follow common procedures, from obtaining consent to the lab testing itself.”  

You can read the article in full here.


To find out how we can help you deliver the healthcare of the future, contact us now or click here for more information.

   
Corporate headquarters
123 Buckingham Palace Road
London SW1W 9SR London SW1W 9SR
United Kingdom
Tel: +44 20 7333 5865 Tel: +44 20 7333 5865
contact us now

NEWS UPDATES

Sign-up to receive company updates and press releases by email or newsfeed:

SIGN-UP

 

By using this website, you accept the use of cookies. For more information on how to manage cookies, please read our privacy policy.

×